Immunogenicity of Current and New Therapies for Hemophilia A

Anti-drug antibody (ADA) development is a significant complication in the treatment of several conditions. For decades, the mainstay of hemophilia A treatment was the replacement of deficient coagulation factor VIII (FVIII) to restore hemostasis, control, and prevent bleeding events. Recently, new p...

Descripción completa

Detalles Bibliográficos
Autores principales: Prezotti, Alessandra N. L., Frade-Guanaes, Jéssica O., Yamaguti-Hayakawa, Gabriela G., Ozelo, Margareth C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331070/
https://www.ncbi.nlm.nih.gov/pubmed/35893734
http://dx.doi.org/10.3390/ph15080911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331070/
https://www.ncbi.nlm.nih.gov/pubmed/35893734
http://dx.doi.org/10.3390/ph15080911

Ejemplares similares